GRI Bio Statistics
Total Valuation
GRI Bio has a market cap or net worth of $6.30 million. The enterprise value is -$4.61 million.
| Market Cap | 6.30M |
| Enterprise Value | -4.61M |
Important Dates
The last earnings date was Friday, August 14, 2026, before market open.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GRI Bio has 2.19 million shares outstanding. The number of shares has increased by 2,639.07% in one year.
| Current Share Class | 2.19M |
| Shares Outstanding | 2.19M |
| Shares Change (YoY) | +2,639.07% |
| Shares Change (QoQ) | +45.44% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 4.28% |
| Float | 2.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.61 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.30, with a Debt / Equity ratio of 0.00.
| Current Ratio | 10.30 |
| Quick Ratio | 9.95 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -142.02% and return on invested capital (ROIC) is -88.03%.
| Return on Equity (ROE) | -142.02% |
| Return on Assets (ROA) | -70.93% |
| Return on Invested Capital (ROIC) | -88.03% |
| Return on Capital Employed (ROCE) | -94.14% |
| Weighted Average Cost of Capital (WACC) | 1.24% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.41M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.95% in the last 52 weeks. The beta is -0.55, so GRI Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.55 |
| 52-Week Price Change | -92.95% |
| 50-Day Moving Average | 1.73 |
| 200-Day Moving Average | 7.12 |
| Relative Strength Index (RSI) | 76.86 |
| Average Volume (20 Days) | 869,542 |
Short Selling Information
The latest short interest is 127,075, so 5.81% of the outstanding shares have been sold short.
| Short Interest | 127,075 |
| Short Previous Month | 110,031 |
| Short % of Shares Out | 5.81% |
| Short % of Float | 5.81% |
| Short Ratio (days to cover) | 0.38 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.68M |
| Pretax Income | -9.66M |
| Net Income | -9.66M |
| EBITDA | -9.68M |
| EBIT | -9.68M |
| Earnings Per Share (EPS) | -$11.55 |
Balance Sheet
The company has $10.95 million in cash and $44,000 in debt, with a net cash position of $10.90 million or $4.99 per share.
| Cash & Cash Equivalents | 10.95M |
| Total Debt | 44,000 |
| Net Cash | 10.90M |
| Net Cash Per Share | $4.99 |
| Equity (Book Value) | 10.28M |
| Book Value Per Share | 4.70 |
| Working Capital | 10.23M |
Cash Flow
In the last 12 months, operating cash flow was -$10.42 million and capital expenditures -$3,000, giving a free cash flow of -$10.42 million.
| Operating Cash Flow | -10.42M |
| Capital Expenditures | -3,000 |
| Depreciation & Amortization | 3,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.42M |
| FCF Per Share | -$4.77 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GRI Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2,639.07% |
| Shareholder Yield | -2,639.07% |
| Earnings Yield | -153.41% |
| FCF Yield | -165.47% |
Analyst Forecast
The average price target for GRI Bio is $18.50, which is 542.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.50 |
| Price Target Difference | 542.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 26, 2026. It was a reverse split with a ratio of 1:28.
| Last Split Date | Jan 26, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:28 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |